Quarterly report pursuant to Section 13 or 15(d)

ASSET ACQUISITION (Details)

v3.23.3
ASSET ACQUISITION (Details)
$ in Millions
 1 Months Ended 9 Months Ended
Jan. 31, 2022
USD ($)
item
Sep. 30, 2023
item
Asset Acquisition    
Number of branded drugs in product portfolio | item 8 8
Minocycline products    
Asset Acquisition    
Asset acquisition interest 4.00%  
Molecule Stabilizing Technology    
Asset Acquisition    
Asset acquisition interest 1.50%  
Vyne product acquisition    
Asset Acquisition    
Upfront payment $ 20.0  
Additional payment 5.0  
One-time payment $ 450.0  
Percentage of upfront payment received 10.00%  
Vyne product acquisition | If annual sales reaches to $100 million    
Asset Acquisition    
Annual sales $ 100.0  
One-time payment 10.0  
Vyne product acquisition | If annual sales reaches to $200 million    
Asset Acquisition    
Annual sales 200.0  
One-time payment 20.0  
Vyne product acquisition | If annual sales reaches to $300 million    
Asset Acquisition    
Annual sales 300.0  
One-time payment 30.0  
Vyne product acquisition | If annual sales reaches to $400 million    
Asset Acquisition    
Annual sales 400.0  
One-time payment 40.0  
Vyne product acquisition | If annual sales reaches to $500 million    
Asset Acquisition    
Annual sales 500.0  
One-time payment $ 50.0